---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-022167"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T16:23:34.144339+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corcept Q1 revenue $157.2M (+7%); FY25 guide $900-950M reaffirmed; relacorilant & dazucorilant updates

## Summary
- Revenue $157.2M, up 7% YoY; diluted EPS $0.17 vs $0.25; operating expenses rose to $153.8M from $117.3M.
- Reiterated FY 2025 revenue guidance $900-950M; cash/investments $570.8M (down from $603.2M due to buybacks).
- Relacorilant NDA for Cushing's under FDA review with PDUFA Dec 30, 2025; NDA for ovarian cancer expected Q3 2025.
- Phase 3 ROSELLA trial met PFS and OS endpoints; results to be presented at ASCO June 2025.
- Dazucorilant ALS trial missed primary endpoint; exploratory survival benefit at 1yr (HR 0.16, p=0.0009); seeking regulatory input.

## SEC filing metadata
- accession: 0001628280-25-022167
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828025022167/0001628280-25-022167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828025022167/cort-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-022167
- JSON: https://secwatch.observer/filing/0001628280-25-022167.json
- Plain text: https://secwatch.observer/filing/0001628280-25-022167.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.